Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB3 vs Herceptin in early or locally advanced HER2-positive breast cancer
CTR20200046Phase 3Terminated
- Sponsor
- iMed Medical
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab-dttb in breast cancer, HER2-enriched breast cancer (HER2+), sponsored by iMed Medical. Started Feb 2020; status: terminated.
02
Drugs
trastuzumab-dttb
03
Conditions
breast cancerHER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on CTR20200046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200046.